Integra LifeSciences Announces Positive Clinical Results for Integra Bilayer Wound Matrix (IBWM) - Seite 2

“In complex lower extremity reconstruction, no approach is completely effective in all situations and contexts, and our recent publications highlight the key scenarios where skin substitutes can be optimally positioned for maximal clinical success,” said John P. Fischer, M.D, plastic surgeon and assistant professor of surgery and director of clinical research at University of Pennsylvania Health System. “Our findings identify key relative advantages with respect to operative efficiency and hospital utilization that align with current issues caused by the COVID-19 pandemic.”

“Lower extremity reconstruction can be challenging and costly for both the patient and health care system. Our goal is to choose an appropriate treatment algorithm, including dermal constructs, that restores function while providing economic benefits,” said Stephen J. Kovach, M.D., plastic surgeon and Herndon B. Lehr endowed associate professor of surgery at the University of Pennsylvania Health System.

Over the last 30 years, Integra Dermal Matrices have been studied in more than 300 clinical trials and studies. They have helped nearly one million patients recover and restore functionality so they can live their lives. For more information please visit our Integra Bilayer Wound Matrix Product Page on www.integralife.com.

^1. Chandan K. Sen, Ph.D., Human Wounds and Its Burden: An Updated Compendium of Estimates, ADVANCES IN WOUND CARE, VOLUME 8, NUMBER 2

Summary of Study Results
The first clinical publication reviews the efficacy of the Integra Bilayer Wound Matrix for lower extremity soft tissue reconstruction.  With 70% of the wounds successfully salvaged at the 180-day timepoint, the authors were able to identify success factors across patient selection and wound types. 

The second publication reviewed cost and resource utilization comparing Integra Bilayer Wound Matrix, Local Tissue Rearrangement (LTR) and Free Flap (FF).  This study showed significantly longer surgery time at 85 and 408 minutes for LTR and FF respectively, compared with 50 minutes for Integra Bilayer Wound Matrix.  It also reported more than double the length of stay in the hospital for both LTR and FF versus Integra Bilayer Wound Matrix. Lastly, total cost of the surgery was $53,492 for FF, $35,220 for LTR and $34,877 for Integra Bilayer Wound Matrix.  Given the shorter operating time and the potential lower cost, Integra Bilayer Wound Matrix may represent an opportunity for patients, surgeons and hospitals during the current situation.